Savant covers the Healthcare sector, focusing on stocks such as Hologic, Illumina, and Thermo Fisher. According to TipRanks, Savant has an average return of -14.9% and a 28.41% success rate on recommended stocks.
Seer has an analyst consensus of Hold, with a price target consensus of $10.00, implying a 39.66% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Hold rating on the stock with a $10.00 price target.
Based on Seer’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $3.57 million and a GAAP net loss of $22.82 million. In comparison, last year the company earned a revenue of $1.22 million and had a GAAP net loss of $16.62 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.
Read More on SEER: